Please select the option that best describes you:
What is your preferred regimen for triple positive breast cancer with visceral metastasis while on adjuvant AI?
Would you consider using CKD inhibitors upfront in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Herceptin
Answer from: Medical Oncologist at Community Practice
My preferred regimen in this clinical situation would be to start with a taxane-based regimen plus trastuzumab and pertuzumab, per the CLEOPATRA trial. In this study, there is a highly significant and clinically meaningful overall survival advantage to adding pertuzumab in patients with newly metast...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree with @Kevin Kalinsky that THP is typically the preferred 1st line strategy in patients with HER2+ disease of any HR status when visceral metastases are present. However, in patients with triple positive disease without visceral metastases one might consider other strategies. For example...